Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Improvement of Sperm Quality in Hyperviscous Semen following DNase I Treatment.

Nosi E, Gritzapis AD, Makarounis K, Georgoulias G, Kapetanios V, Varla-Leftherioti M, Venieratos P, Papanikopoulos C, Konstantinidou A, Tsilivakos V.

Int J Endocrinol. 2019 May 29;2019:6325169. doi: 10.1155/2019/6325169. eCollection 2019.

2.

Flow cytometry analysis of CD4+IFN-γ+ T-cells for the diagnosis of mycobacterium tuberculosis infection.

Papageorgiou CV, Anastasopoulos A, Ploussi M, Leventopoulos M, Karabela S, Fotiadis K, Papavasileiou A, Vogiatzakis E, Ioakeimidis D, Gritzapis AD, Poulakis N.

Cytometry B Clin Cytom. 2016 May;90(3):303-11. doi: 10.1002/cyto.b.21275. Epub 2015 Sep 8.

3.

Intracellular ESAT-6: A new biomarker for Mycobacterium tuberculosis infection.

Poulakis N, Gritzapis AD, Ploussi M, Leventopoulos M, Papageorgiou CV, Anastasopoulos A, Constantoulakis P, Karabela S, Vogiatzakis E, Tsilivakos V.

Cytometry B Clin Cytom. 2016 May;90(3):312-4. doi: 10.1002/cyto.b.21220. Epub 2015 Feb 6.

4.

Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer.

Xynos ID, Karadima ML, Voutsas IF, Amptoulach S, Skopelitis E, Kosmas C, Gritzapis AD, Tsavaris N.

Oncology. 2013;84(5):273-83. doi: 10.1159/000343282. Epub 2013 Feb 22.

PMID:
23445638
5.

Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab.

Voutsas IF, Mahaira LG, Fotopoulou K, Kapranos N, Reclos JG, Gritzapis AD, Papamichail M, Perez SA, Baxevanis CN.

Int J Radiat Biol. 2013 May;89(5):319-25. doi: 10.3109/09553002.2013.765617. Epub 2013 Feb 1.

PMID:
23311575
6.

Identification of novel breast cancer-associated transcripts by UniGene database mining and gene expression analysis in normal and malignant cells.

Laversin SA, Phatak VM, Powe DG, Li G, Miles AK, Hughes DC, Ball GR, Ellis IO, Gritzapis AD, Missitzis I, McArdle SE, Rees RC.

Genes Chromosomes Cancer. 2013 Mar;52(3):316-29. doi: 10.1002/gcc.22031. Epub 2012 Dec 8.

PMID:
23225347
7.

Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.

Gritzapis AD, Voutsas IF, Baxevanis CN.

Cancer Immunol Immunother. 2012 Mar;61(3):397-407. doi: 10.1007/s00262-011-1113-4. Epub 2011 Sep 18.

PMID:
21928125
8.

Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.

Tsavaris N, Voutsas IF, Kosmas C, Gritzapis AD, Baxevanis CN.

Invest New Drugs. 2012 Feb;30(1):395-402. doi: 10.1007/s10637-010-9533-0. Epub 2010 Sep 7.

PMID:
20820907
9.

HER-2/neu as a target for cancer vaccines.

Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M.

Immunotherapy. 2010 Mar;2(2):213-26. doi: 10.2217/imt.09.89. Review.

PMID:
20635929
10.

Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.

Gritzapis AD, Voutsas IF, Lekka E, Papamichail M, Baxevanis CN.

Cancer Res. 2010 Apr 1;70(7):2686-96. doi: 10.1158/0008-5472.CAN-09-2517. Epub 2010 Mar 16.

11.

A new era in anticancer peptide vaccines.

Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN.

Cancer. 2010 May 1;116(9):2071-80. doi: 10.1002/cncr.24988. Review.

12.

Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy.

Lekka E, Gritzapis AD, Perez SA, Tsavaris N, Missitzis I, Mamalaki A, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2010 May;59(5):715-27. doi: 10.1007/s00262-009-0791-7. Epub 2009 Nov 11.

PMID:
19904532
13.

HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties.

Gritzapis AD, Fridman A, Perez SA, La Monica N, Papamichail M, Aurisicchio L, Baxevanis CN.

Vaccine. 2009 Dec 10;28(1):162-70. doi: 10.1016/j.vaccine.2009.09.104. Epub 2009 Sep 30.

PMID:
19799847
14.

Mannose addition by yeast Pichia Pastoris on recombinant HER-2 protein inhibits recognition by the monoclonal antibody herceptin.

Vlahopoulos S, Gritzapis AD, Perez SA, Cacoullos N, Papamichail M, Baxevanis CN.

Vaccine. 2009 Jul 23;27(34):4704-8. doi: 10.1016/j.vaccine.2009.05.063. Epub 2009 Jun 9.

PMID:
19520203
15.

Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.

Gritzapis AD, Voutsas IF, Lekka E, Tsavaris N, Missitzis I, Sotiropoulou P, Perez S, Papamichail M, Baxevanis CN.

J Immunol. 2008 Jul 1;181(1):146-54.

16.

Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain.

Voutsas IF, Gritzapis AD, Mahaira LG, Salagianni M, von Hofe E, Kallinteris NL, Baxevanis CN.

Int J Cancer. 2007 Nov 1;121(9):2031-41.

17.

A novel quantitative flow cytometric method for measuring glucocorticoid receptor (GR) in cell lines: correlation with the biochemical determination of GR.

Voutsas IF, Gritzapis AD, Alexis MN, Katsanou ES, Perez S, Baxevanis CN, Papamichail M.

J Immunol Methods. 2007 Jul 31;324(1-2):110-9. Epub 2007 Jun 8.

PMID:
17582432
18.

Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.

Sotiriadou NN, Kallinteris NL, Gritzapis AD, Voutsas IF, Papamichail M, von Hofe E, Humphreys RE, Pavlis T, Perez SA, Baxevanis CN.

Cancer Immunol Immunother. 2007 May;56(5):601-13. Epub 2006 Sep 8.

PMID:
16960693
19.

Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.

Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN.

Cancer Res. 2006 May 15;66(10):5452-60.

20.

Effect of IL-21 on NK cells derived from different umbilical cord blood populations.

Perez SA, Mahaira LG, Sotiropoulou PA, Gritzapis AD, Iliopoulou EG, Niarchos DK, Cacoullos NT, Kavalakis YG, Antsaklis AI, Sotiriadou NN, Baxevanis CN, Papamichail M.

Int Immunol. 2006 Jan;18(1):49-58. Epub 2005 Nov 15.

PMID:
16291655
21.

Interactions between human mesenchymal stem cells and natural killer cells.

Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M.

Stem Cells. 2006 Jan;24(1):74-85. Epub 2005 Aug 11.

22.

Beneficial effect of short-term exposure of human NK cells to IL15/IL12 and IL15/IL18 on cell apoptosis and function.

Sotiriadou NN, Perez SA, Gritzapis AD, Mahaira LG, Salagianni M, Baxevanis CN, Papamichail M.

Cell Immunol. 2005 Mar;234(1):67-75.

PMID:
16024007
23.

Immunogenic HER-2/neu peptides as tumor vaccines.

Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, Papamichail M.

Cancer Immunol Immunother. 2006 Jan;55(1):85-95. Epub 2005 Oct 27. Review.

PMID:
15948002
24.

CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells.

Ioannidis P, Mahaira LG, Perez SA, Gritzapis AD, Sotiropoulou PA, Kavalakis GJ, Antsaklis AI, Baxevanis CN, Papamichail M.

J Biol Chem. 2005 May 20;280(20):20086-93. Epub 2005 Mar 14.

25.

A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survival.

Perez SA, Mahaira LG, Demirtzoglou FJ, Sotiropoulou PA, Ioannidis P, Iliopoulou EG, Gritzapis AD, Sotiriadou NN, Baxevanis CN, Papamichail M.

Blood. 2005 Jul 1;106(1):158-66. Epub 2005 Mar 8.

PMID:
15755904
26.
27.

Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2).

Phenekos C, Vryonidou A, Gritzapis AD, Baxevanis CN, Goula M, Papamichail M.

Neuroimmunomodulation. 2004;11(4):209-13.

PMID:
15249726
28.

Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.

Gritzapis AD, Sotiriadou NN, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2004 Nov;53(11):1027-40. Epub 2004 May 26.

PMID:
15164233
29.

Natural killer lymphocytes: biology, development, and function.

Papamichail M, Perez SA, Gritzapis AD, Baxevanis CN.

Cancer Immunol Immunother. 2004 Mar;53(3):176-86. Epub 2003 Dec 18. Review.

PMID:
14685782
30.

In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.

Baxevanis CN, Gritzapis AD, Papamichail M.

J Immunol. 2003 Sep 15;171(6):2953-9.

31.

Quantitative fluorescence cytometric measurement of estrogen and progesterone receptors: correlation with the hormone binding assay.

Gritzapis AD, Baxevanis CN, Missitzis I, Katsanou ES, Alexis MN, Yotis J, Papamichail M.

Breast Cancer Res Treat. 2003 Jul;80(1):1-13.

PMID:
12889594
32.

In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI.

Mamalaki A, Gritzapis AD, Kretsovali A, Belimezi M, Papamatheakis J, Perez SA, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2003 Aug;52(8):513-22. Epub 2003 Apr 25.

PMID:
12715240
33.

Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.

Gritzapis AD, Mamalaki A, Kretsovali A, Papamatheakis J, Belimezi M, Perez SA, Baxevanis CN, Papamichail M.

Br J Cancer. 2003 Apr 22;88(8):1292-300.

34.

A novel myeloid-like NK cell progenitor in human umbilical cord blood.

Perez SA, Sotiropoulou PA, Gkika DG, Mahaira LG, Niarchos DK, Gritzapis AD, Kavalakis YG, Antsaklis AI, Baxevanis CN, Papamichail M.

Blood. 2003 May 1;101(9):3444-50. Epub 2002 Dec 27.

PMID:
12506032
35.

Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants.

Gritzapis AD, Dimitroulopoulos D, Paraskevas E, Baxevanis CN, Papamichail M.

Cancer Immunol Immunother. 2002 Oct;51(8):440-8. Epub 2002 Aug 1.

PMID:
12202905
36.

HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.

Baxevanis CN, Gritzapis AD, Tsitsilonis OE, Katsoulas HL, Papamichail M.

Int J Cancer. 2002 Apr 20;98(6):864-72.

37.

Efficacy of novel culture environments on the ex vivo expansion kinetics of cord blood progenitor cells.

Cacoullos NT, Gritzapis AD, Tsitsilonis AE, Tsiatas ML, Baxevanis CN, Papamichail M.

Haematologica. 2002 Mar;87(3):320-1.

38.

HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones.

Perez SA, Sotiropoulou PA, Sotiriadou NN, Mamalaki A, Gritzapis AD, Echner H, Voelter W, Pawelec G, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2002 Jan;50(11):615-24. Epub 2001 Nov 23.

PMID:
11807625
39.

Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.

Sotiriadou R, Perez SA, Gritzapis AD, Sotiropoulou PA, Echner H, Heinzel S, Mamalaki A, Pawelec G, Voelter W, Baxevanis CN, Papamichail M.

Br J Cancer. 2001 Nov 16;85(10):1527-34.

40.

A novel culture environment for generating mature human dentritic cells from peripheral blood CD14+ cells.

Tsiatas ML, Gritzapis AD, Cacoullos NT, Papadhimitriou SI, Baxevanis CN, Papamichail M.

Anticancer Res. 2001 Mar-Apr;21(2A):1199-206.

PMID:
11396164
41.

Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients.

Theodoropoulou S, Spanakos G, Baxevanis CN, Economou M, Gritzapis AD, Papamichail MP, Stefanis CN.

Schizophr Res. 2001 Jan 15;47(1):13-25.

PMID:
11163541
42.

Synergy between interleukin-2 and prothymosin alpha for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas.

Voutsas IF, Baxevanis CN, Gritzapis AD, Missitzis I, Stathopoulos GP, Archodakis G, Banis C, Voelter W, Papamichail M.

Cancer Immunol Immunother. 2000 Oct;49(8):449-58.

PMID:
11043852
43.

Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice.

Baxevanis CN, Voutsas IF, Tsitsilonis OE, Tsiatas ML, Gritzapis AD, Papamichail M.

Eur J Immunol. 2000 Jul;30(7):1957-66.

44.

Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.

Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M.

J Immunol. 2000 Apr 1;164(7):3902-12.

45.

Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alpha.

Baxevanis CN, Spanakos G, Voutsas IF, Gritzapis AD, Tsitsilonis OE, Mamalaki A, Papamichail M.

Cancer Immunol Immunother. 1999 May-Jun;48(2-3):71-84.

PMID:
10414460
46.

Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity.

Baxevanis CN, Voutsas IF, Soler MH, Gritzapis AD, Tsitsilonis OE, Stoeva S, Voelter W, Arsenis P, Papamichail M.

Immunopharmacol Immunotoxicol. 1998 Aug;20(3):355-72.

PMID:
9736441
47.

Production and characterization of a monoclonal antibody against epirubicin.

Papadopoulos NG, Gritzapis AD, Dedoussis GV, Spanakos G, Baxevanis CN, Papamichail M.

Hybridoma. 1995 Dec;14(6):593-6.

PMID:
8770648
48.

Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.

Baxevanis CN, Gritzapis AD, Spanakos G, Tsitsilonis OE, Papamichail M.

Cancer Immunol Immunother. 1995 Jun;40(6):410-8.

PMID:
7543022
49.

An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry.

Papadopoulos NG, Dedoussis GV, Spanakos G, Gritzapis AD, Baxevanis CN, Papamichail M.

J Immunol Methods. 1994 Dec 28;177(1-2):101-11.

PMID:
7822816
50.

Interleukin 1 beta synergises with interleukin 2 in the outgrowth of autologous tumour-reactive CD8+ effectors.

Baxevanis CN, Dedoussis GV, Gritzapis AD, Stathopoulos GP, Papamichail M.

Br J Cancer. 1994 Oct;70(4):625-30.

Supplemental Content

Loading ...
Support Center